@article{4fb273c4147e42fe8a8ed03d72a8e21d,
title = "Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: A survey of 796 outpatients in Japan",
abstract = "Since the literature on benzodiazepine use in elderly patients with anxiety disorders is limited, a large cross-sectional review of psychotropic prescriptions in 796 patients with neurotic disorders (ICD-10) (age range = 11-91 years) was conducted across 30 sites in Japan. Use of benzodiazepine-derivative anxiolytics was approximately 70% in all decades without a group difference. The proportion of subjects who received prescriptions for benzodiazepine-derivative anxiolytics in the absence of antidepressants was higher in older age groups (e.g., 27.7% and 43.2% in the third and sixth decades, respectively). On the other hand, antidepressants were less frequently prescribed in older age groups (e.g., 59.8% and 41.5% in the third and sixth decades, respectively). The very high use of anxiolytics in the elderly, especially in the absence of concomitant antidepressant use, is a cause for concern since they are not a preferred long-term treatment strategy given their adverse effects in the elderly.",
keywords = "Aging, Antidepressant, Anxiety disorder, Benzodiazepine, Elderly, Neurotic disorder",
author = "Hiroyuki Uchida and Takefumi Suzuki and Mamo, {David C.} and Mulsant, {Benoit H.} and Toshiaki Kikuchi and Hiroyoshi Takeuchi and Masayuki Tomita and Koichiro Watanabe and Gohei Yagi and Haruo Kashima",
note = "Funding Information: Dr. Uchida's fellowship has been supported by the Japanese Society of Clinical Psychopharmacology, Pfizer Health Research Foundation, and Mochida Memorial Foundation. Within the past 5 years, Dr. Uchida has received speaker's honoraria or manuscript fees from GlaxoSmithKlein, Otsuka, and Dainippon Sumitomo Pharma. Funding Information: Dr. Kikuchi has received a research grant from GlaxoSmithKlein within the past 5 years. Funding Information: Dr. Mamo has received grants, consultant fees, and other financial support from the Canadian Psychiatric Research Foundation, the Schizophrenia Society of Canada, the Stanley Medical Research Institute, and Bristol-Myers Squibb, and has received speaker's honoraria from Astra Zeneca within the past 5 years. Funding Information: Dr. Mulsant holds stock in Akzo-Nobel, Alkermes, AstraZeneca, Biogen Idec, Celsion, Elan, Eli Lilly, Forest, General Electric, Immune Response, and Pfizer. Within the past 5 years, he has received grants, consultant fees and other financial support from the National Institute of Health, Eli Lilly, Forest, Jansen, Fox Learning System, Lundbeck, and Pfizer. Within the past 5 years, he has been a member of the speakers{\textquoteright} bureaus of AstraZeneca, Forest, and Pfizer. ",
year = "2009",
month = may,
doi = "10.1016/j.janxdis.2008.10.003",
language = "English",
volume = "23",
pages = "477--481",
journal = "Journal of Anxiety Disorders",
issn = "0887-6185",
publisher = "Elsevier Limited",
number = "4",
}